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Summary
Background: The identification of new factors predicting
relapse, outcome and response to systemic therapy in breast
cancer is warranted. The measurement of biological markers
such as drug resistance parameters (DRPs), which are part of
the phenotype of malignant cells and contribute to resistance
to anti-cancer drugs may be a possibility, which may ultimately
lead to improvement of therapeutic results.
Patients and methods: The level of glutathione (GSH),
activities of glutathione-S-transferase (GST), glutathione-per-
oxidase (GPx), 06-alkylguanine-DNA-alkyltransferase (ATase),
and P-glycoprotein (PGP) were measured in tumor and adja-
cent tumor free tissue samples from 89 consecutive, untreated
females with breast cancer and correlated with clinical and
prognostic factors. Early breast cancer (EBC) was diagnosed
in 56 patients, 22 patients had locally advanced (LABC) and 11
patients metastatic breast cancer.
Results: All DRPs showed significantly higher expression
in tumor than in tumor free tissues. GPx was positively cor-
related with GST (r = 0.3, P = 0.0048) and with GSH (r = 0.5,
P = 0.0001) in tumor as well as in normal tissue. GST activity
was significantly higher in EBC than in LABC or metastatic
breast cancer (P = 0.02). GSH level was significantly higher in
grade 1 than in grade 2 or grade 3 tumors {P = 0.01). When
clinical characteristics were related to the level of DRP, 'high'
GSH was associated with age > 60 years (P = 0.01) in EBC,
and with grade 1-2 tumors (P = 0.05) in LABC. No differences
in OS were apparent between groups of 'high' and 'low' DRP-
expression. However, the four-year estimated disease-free sur-
vival of EBC tended to be higher in patients with 'high' GST
(P = 0.10) and of LABC in patients with 'high' GPx levels (P -
0.06).
Conclusion. We conclude that 'high' levels of DRP in tumor
tissue of breast cancer patients are part of the initial phenotype
of the malignant cells. Due to its high prevalence (83% in EBC,
100% in primarily metastatic breast cancer), PGP did not add
to prognostic information. High levels of GSH, GST and and
GPx were associated with favorable clinical characteristics and
good prognosis, whereas low levels of GSH and GST activity
were associated with more aggressive or more advanced disease.
Key words: ATase, breast cancer, drug resistance, PGP, GPx,
GSH, GST, prognosis
Introduction
Breast cancer has become the second leading cause of
cancer deaths in women after lung cancer [1]. Currently,
none of the known prognostic factors in breast cancer
are capable of fully defining the patients with highest
risk for relapsing disease [2]. Therefore, the identification
of new factors predicting relapse, outcome and response
to systemic therapy is warranted. The measurement of
biological markers, which are part of the phenotype of
malignant cells and contribute to resistance to anti-
cancer drugs, may be a possibility, which may ultimately
lead to improvement of therapeutic results.
Current clinical investigations try to circumvent
resistance pathways, by adding resistance modulators,
previously identified as modulators in vitro, to chemo-
therapeutic regimens. So far, results remain behind
expectations [3], suggesting that therapy response in
most cases may depend on more than one parameter
and that the modulators may not be specific and/or
effective enough. While most studies focus on one
parameter, the aim of this study was to measure P-glyco-
protein (PGP), glutathione (GSH), GSH-S-transferases
(GST), glutathione-peroxydase (GPx) and O6-alkyl-
guanine-DNA alkyltransferase (ATase) simultaneously
in tumor samples of patients with newly diagnosed early,
locally advanced and metastatic breast cancer as well as
normal breast tissue of the same patients.
The best understood drug resistance parameter is
PGP, a 170-kd protein coded for by the MDR1 gene,
which works as an energy-dependent efflux pump to
decrease intracellular accumulation of a number of
cytostatic drugs [4]. PGP expression was found in a
majority of tumor specimens in patients with breast
cancer. Although high PGP expression appears to cor-
relate with poor response to chemotherapy and short
disease-free survival in some instances [5], its role is still
controversial. Some evidence suggests that PGP may
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also be a marker of 'biological maliciousness' of cancers
[6].
Subsequently, other biochemical parameters, which
play an important role in the detoxification or cell repair
systems, were identified. Although many of them were
shown to contribute to drug resistance in vitro, a direct
connection, between these parameters and drug resist-
ance in vivo has not yet been established. GSH plays an
important role in detoxification and repair of cellular
injury caused by cyclophosphamide, nitrosoureas and
quinone antibiotics [7]. Elevated levels of GSH have
been described in different human tumor tissue samples
when compared with normal tissue [8, 9].
GSTs are a family of enzymes which catalyse the
conjugation of electrophilic substrates with GSH, there-
by detoxifying them. Increased levels of these enzymes
have been found in human breast cancer when com-
pared with benign lesions [10]. GST-7T. expression, one
of the four different classes of GST known in humans,
was reported to be inversely correlated with hormone
receptor status in breast cancer [11]. GPx, an enzyme
removing toxic oxygen intermediates, is also associated
with GSH. GPx activity was found at increased levels in
breast cancer when compared to normal tissue [12].
ATase is an enzyme involved in DNA repair and is
present in all human tissues [13]. Many human tumor
tissues show higher activity than corresponding normal
tissue. However, so far no differences in ATase activity
between breast cancer and corresponding normal breast
tissue have been reported [14].
Despite the great amount of information about GSH,
GST, GPx, and ATase, and their involvement in the
cellular defense against toxic substances, association
with either clinical behavior or prognosis has yet to be
established.
We attempted to evaluate whether the simultaneous
assessment of these parameters would allow detection of
a distinct pattern of distribution in tumor tissues and
whether an association between any of these parameters
and established prognostic factors and/or clinical out-
come could be found.
Patients and methods
Patient characteristics
From May 1988 until November 1991. 89 nonsdected Caucasian female
patients with histologically proven breast cancer, but no other cancer,
were evaluated. None of the patients had received any systemic treat-
ment. The patients characteristics are presented in Table 1 The median
follow-up from diagnosis is 45 months. Relapse or disease progression
was observed in 34 patients, 30 patients died during follow-up and of
these six patients died without relapse or progression (one cerebro-
vascular insult, three cardiovascular disease, one influenza, one pneu-
monia).
Tissue collection
Tumor tissue and tumor-free tissue samples were obtained from the
operating theater at first surgery. Tissue samples were snap frozen and
maintained at -70 "C until assayed.
Pathologic examination
The pathology reports and the histological slides of the tumors were
evaluated by a board-certified pathologist. The histological determina-
tion of the tumor type was performed according to the WHO clas-
sification. Histological tumor grading was performed according
to Elston and Ellis [15]. Tissue samples from tumor and tumor-free
tissue samples were used for pathologic review It was confirmed by
the pathologist that the tissue samples examined for histology were
directly adjacent to the sample used for the biochemichal assays.
The tumor mass, estimated on the corresponding histological
slides, ranged between 15% and 90%, the remaining tissue consisted
of desmoplastic stromal fibrosis and fat tissue. None of the tumor
samples contained relevant necrosis and none of the samples from
tumor-free breast tissue revealed any breast cancer cells. For the
steroid hormone receptor determination the dextrane coated charcoal
method (DCC) was used [16]. Patients were designated as hormone-
receptor positive (progesterone receptor > 20 fmol/mg protein and/or
estrogen receptor >10 fmol/mg protein) or hormone-receptor nega-
tive (progesterone receptor <20 fmol/mg protein and/or estrogen
receptor < 10 fmol/mg protein).
Tissue preparation
Techniques of sample preparation and assays have been described in a
previous report [8]
Table 1. Patient characteristics.
Number of patients
Median age (years)
Range
Clinical stage (TNM)
Early primary breast cancer (TI-T2, Nl , M0,
T3aN0M0)
Advanced breast cancer (T3-T4, N2 or N3, M0)
Primarily metastatic breast cancer (T1-T4, N0-N3,
Ml)
Histology
Invasive ductal carcinoma
Lobular invasive carcinoma
Medullary carcinoma
Mucinous carcinoma
Grading
Grade 1
Grade 2
Grade 3
Hormone-receptor status
Positive
Negative
Axillary lymph node status
Positive
Negative
Menstrual status
Premenopausal
Postmenopausal
Adjuvant therapy
Chemotherapy ± radiotherapy
Hormones ± radiotherapy
Chemotherapy + hormones ± radiotherapy
Radiotherapy alone
None
No. (%)
89(100%)
68
(33-89)
56 (63%)
22 (25%)
11 (12%)
71 (80%)
9(10%)
6 (7%)
3 (3%)
3 (3%)
60 (68%)
26 (29%)
78 (88%)
11(12%)
31 (35%)
58 (65%)
19(21%)
70 (79%)
17(19%)
41 (46%)
8 (9%)
1(1%)
22 (25%)
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Enzyme assays and Western blotting
GSH content was measured according to Tietze's recycling assay.
Overall GST activity was measured according to the method of Habig.
GPx activity was assayed with the improved method of Gunzler. For
enzyme assays several data points in the linear response range were
used and the results were calculated per mg of protein in the cytoplas-
matic fraction as determined using Bradford's reagent with bovine
serum albumin as standard.
ATase was measured according to the method of Morten and
Margison and calculated as fmol methyl transferred to protein per ug
DNA.
PGP was determined semi-quantitatively by Western blot after
separation of membrane proteins by SDS-PAGE [8]. The antibody
used was a polyclonal rabbit antiserum raised against amino acids
1205-1224 of the human mdr protein. This peptide (ALDTESEKVV-
QEALDKAREG) was made for us by Multiple Peptide Systems, Inc.,
San Diego, CA The antibody used recognizes the gene products of
both MDR1 and MDR3. In the tissue samples analyzed, however,
MDR3 is not ecpected to contribute the the signals detected, since no
MDR3 expression has been found in human breast tissue. Positive and
negative controls were crude membrane pellets from the doxorubicin-
resistant lung cancer cell line SW 1573 IR 500-0 and its drug sensitive
parent SW 1573, generously provided by Dr. H. Joenje, Amsterdam.
All gels included internal standards consisting of three different
amounts of membrane protein from the positive control. The signals
produced by PGP were compared to the internal standards and three
categories were arbitrarily defined: 1) no detectable signal = 0 (nega-
tive); 2) weakly positive signal = + (PGP-signal weaker than one
produced by 1.25 ug protein of the positive control) and 3) strongly
positive signal = ++ (PGP-signal equal to or stronger than the one
produced by 1.25 ug protein of the positive control). For practical
reasons, in the result presentation, we grouped together weakly and
strongly positive PGP (labeled as 'positive').
All analyses were performed with the investigators unaware of the
patients' characteristics and outcome.
Statistical methods
Differences between expression/activities of GSH, ATase, GST, and
GPx in normal breast and tumor tissue were calculated for each
patient, and the 'paired' Wilcoxon signed rank test was used to test
the hypothesis of no difference. Correlation between different DRPs
was measured with the Spearmann rank correlation coefficient The
Wilcoxon rank-sum test or the Kruskal-Wallis test were used to
compare the distribution of the DRPs according to clinical and
prognostic parameters. In case of ordered groups (clinical stage and
grade) a non parametric test for trend was performed [17]. The
relationship between PGP levels and other parameters was determined
with the chi-square or Fisher's exact test where appropriate Values
of DRPs except for PGP expression/activity were divided into 2 groups
taking the median values as cutting point ( ^ median:'low', > median:
'high'). This decision was made a priori, before examination of the
results for outcome and prognosis. The Kaplan-Meier method was
used to estimate distributions of disease-free survival (DFS), time to
progression (TTP), and overall survival (OS) [18]. The estimates are
reported with standard errors. Differences in time distributions were
evaluated by the log-rank test [19]. P-values < 0.05 were considered to
be statistically significant. All F-values were derived from two-sided
tests for significance. No adjustment for multiple comparison was
performed.
Results
DRP expression in normal breast and tumor tissue
Significantly higher levels of all tested DRPs were found
in tumor tissue compared to normal breast tissue. More-
over, in normal tissue GPx activity significantly cor-
related with GST activity (r = 0.48, P - 0.0001) and with
GSH levels (r = 0.51, P = 0.0001). Similarly, in tumor
tissue a significant correlation of GPx activity with GST
(r = 0.3, P = 0.0048) and GSH (r = 0.52, P = 0.0001) was
observed.
Biological behavior and outcome is different in pa-
tients with EBC as compared to patients with LABC or
primary metastatic breast cancer. These three groups of
patients were therefore separated for further analyses.
GST activities were high in early and decreased in
locally advanced and metastatic breast cancer (median
values: 62.6 vs. 46.9 vs. 35.9 nmol/min/mg protein re-
spectively; test for trend P-value = 0.02; Figure la).
Similarly, GSH-levels were higher in grade 1 than in
grade 2 and 3 tumors (median values: 40.9 vs. 36.9 vs.
22.4 nmol/mg protein, respectively; test for trend P-
value = 0.01; Figure lb).
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Figure 1 (a) Box plots of GST activity in early, locally advanced and
metastatic breast cancer. The line in the middle of the box represents
the median. The box extends from the 25th to the 75th percentile. The
lines emerging from the box extend to the upper and lower 'adjacent
values' Points more extreme are individually plotted, (b) Box plots of
GSH activity in grade 1, 2 and 3 breast cancer. The line in the middle of
the box represents the median. The box extends from the 25th to the
75th percentile. The lines emerging from the box extend to the upper
and lower 'adjacent values'. Points more extreme are individually
plotted.
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DRP expression and clinical characteristics in early
breast cancer
The median levels of DRPs in tumor tissue of EBC-
patients calculated separately for the different clinical
and pathological characteristics (age, histology, grading,
hormone-receptor status, axillary node involvement and
menopausal status) are shown in Table 2a. With one
exception none of the DRPs appeared to be associated
with any of these characteristics. Only the median GSH
level was significantly elevated in patients older than 60
years as compared to younger patients (P - 0.01). PGP
was expressed in the tumors of 44 of 53 patients (83%)
and the frequency of expression was similar for all tested
characteristics (Table 2a). We were interested to see
whether any of the DRPs analyzed influenced OS or
DFS in these patients. No significant differences in OS
or DFS were apparent. However, a trend was found for
GST, the four-year estimated DFS being 74% (SE 8%)
for 'high' and 57% (SE 9%) for 'low' GST activity (log-
rank P = 0.10).
DRP expression and clinical characteristics in locally
advanced breast cancer
Median levels of GSH, ATase, GST, GPx and PGP
activity/expression in tumor tissue of patients with
LABC for the different clinical and pathological charac-
teristics are shown in Table 2b. Again with one exception
none of the DRPs appeared to be associated with any of
these characteristics. Only the median GSH level was
higher in patients with low-grade tumors (P - 0.05)
compared to high grade. PGP expression was found in
15 of 20 patients (75%). The analysis of OS and DFS in
this subgroup of patients revealed no significant differ-
ences but a clear trend for GPx, the four-year estimated
DFS being 75% (SE 16%) for 'high'and 46% (SE 16%)
for 'low' GPx activity (log-rank P = 0.06).
DRP expression in primarily metastatic breast cancer
Eleven of our patients had primarily metastatic breast
cancer. This group was therefore too small to allow a
meaningful correlation between DRPs and prognostic
characteristics. Median values in this group were 29.2
nmol/mg protein for GSH (range 7.16-62.62), 35.9
nmol/min/mg protein for GST (range 6.5-108.2), 8.38
mU/mg protein for GPx (range 1.07-50.5) and 3.85
fmol/ug DNA for ATase (range 0.74-14.76). All 11
patients expressed PGP, without any difference in TTP
for levels of positivity. All patients with metastatic dis-
ease progressed, and all, except one, died during the
observation time.
Discussion
Breast cancer is a disease, which can be treated with
variable success. More valid criteria for defining patients
Table 2a Drug resistance parameters in tumor tissue of early breast
cancer by prognostic characteristics. Median values (% positive for
PGP).
Overall
Range
Age
< 60 years
> 60 years
Histology
Invasive ductal
Other
Grading
1-2
3
n
56
20
36
48
8
43
13
Hormone-receptor status
Negative
Positive
7
49
Axillary node involvement
Negative
Positive
Menopausal status
Premenopausal
Postmenopausal
26
30
12
44
GSH
nmol/mg
protein
35 3
(0-128 6)
23.7"
38.1"
36 8
28 7
36 8
22.9
21.4
36.8
34.9
35 3
26 1
36.9
GST
nmol/
min/mg
protein
62.6
(165-
347.2)
75 3
60.3
62.6
83 1
63 2
57 3
73 1
62.1
65
61 7
73 1
61.2
GPx
mU/mg
protein
9.3
(3.5-
32 2)
7.9
99
9.4
7.3
9.1
109
9.1
9 3
77
10.1
8.1
9.3
Atase
fmol/
ME
DNA
4.6
(0.9-
11 7)
3.3
5.5
4.4
6 4
4 5
5.4
57
4.5
4.7
4.4
3 7
5 1
PGP
% posi-
tive
(n = 53)
83%
89%
79%
80%
100%
78%
100%
100%
80%
78%
87%
100%
78%
1 Significantly different values are in bold (/"-value = 0 01)
Table 2b Drug resistance parameters in tumor tissue of locally
advanced breast cancer by prognostic characteristics. Median values
(% positive for PgP).
Overall
Range
Age
< 60 years
> 60 years
Histology
Invasive ductal
Other
Grading
1-2
3
n
22
6
16
15
7
14
8
Hormone-receptor status
Negative
Positive
2
20
Axillary node involvement
Negative
Positive
Menopausal status
Premenopausal
Postmenopausal
4
18
4
18
GSH
nmol/mg
protein
37 6
(2 5-
85 5)
42 3
35
34.3
52.7
40.1"
24.6"
25.2
39.8
46.5
35
40.3
37.6
GST
nmol/
min/mg
protein
46 9
(19.9-
188 6)
41 5
49.4
43.7
58 5
51.4
41 5
84.9
448
37.1
49.4
41.5
37 6
GPx
mU/mg
protein
8.9
(2-
21.5)
11 6
73
79
11 9
109
72
10 1
8.9
6.1
89
11
8.5
Atase
fmol/
DNA
3 3
(0 5-
10 1)
4.4
3.3
32
4 6
33
3.3
3.6
3 4
2 8
3.4
4 3
3.3
PGP
% posi-
tive
(n = 20)
75%
67%
79%
79%
67%
67%
88%
100%
72%
50%
78%
100%
69%
a Significantly different values are in bold (/"-value = 0.05)
at risk of poor response to chemotherapy would be
helpful. Our study was an attempt to define additional
criteria by measuring the level of expression of several
pretreatment parameters thought to be involved in cyto-
static drug resistance. GSH, GST, GPx and ATase were
all found to be expressed at significantly higher levels
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and PGP was significantly more frequently expressed in
tumor, when compared to tumor-free tissue. Similar
observations have been made for other cancer types [20]
and support the hypothesis that these biological markers
are part of the intrinsic, metabolic pattern of malignant
cells.
The comparison of DRPs in tumor tissue and corre-
sponding normal tissue by biochemical methods has to
be interpreted with caution because the amount of
epithelial cells within the normal tissue fragments is
about 5%-10% whereas the amount of neoplastic cells
in tumor tissue fragments vary from 10%—90%. The
biochemical measurements in normal tissue should only
give an impression on the natural arsenal of DRP in
normal breast tissue. Therefore, the results of the DRP
measurements of normal tissue fragments has not been
included for the correlation with clinical and prognostic
characteristics of the investigate breast cancer.
While PGP is the best studied of all putative DRPs,
its role as prognostic factor is still controversial. Most
authors agree that PGP is present in many cases of
untreated breast cancer. It is not clear, however, whether
its expression may influence treatment outcome. Eighty-
three percent of our patients had detectable levels of
PGP in their tumor tissue. No association with prognos-
tic factors was apparent, a finding that matches the
results of other investigators [21, 22]. Interestingly, how-
ever, all patients with primarily metastatic disease
expressed PGP. This is more extreme than in Linn et al.
[23] where 58% of the samples were PGP positive. PGP
was highly prevalent (83% in EBC, 100% in primarily
metastatic breast cancer), and therefore not adding
further to prognostic information. The semiquantitative
assessment of PGP did not improve its prognostic value.
There was no apparent influence of the level of PGP-
expression on OS, DFS or TTP. Recently, a similar lack
of correlation between PGP-expression and chemother-
apy response or survival was reported by Decker et al.
[24]. Other authors, however, found high PGP-expres-
sion to be associated with a poor response to chemo-
therapy and short DFS [5]. These discrepancies suggest
that more studies are needed in order to clarify the role
of PGP in breast cancer. A major obstacle in comparing
the results from different studies is the use of variable
techniques and reference standards. Thus, while many of
the recently published studies used histochemistry to
detect PGP, we have chosen to assess PGP expression
by Western blot. This was done so as to be able to
perform the measurement of all DRPs on material
derived from the same sample. With this method, how-
ever, it was not possible to localize PGP within the
tissue. Nevertheless, contamination of analyzed tissue
samples e.g., with white blood cells expressing MDR1
and/or MDR3, which are both recognized by our anti-
body, can be neglected, because the level of expression of
PGP in these cells is below the detection limit of our
assay [25].
The overexpression of GSH, GST, GPx and ATase in
the tumor tissue show, that potential drug resistance
mechanisms other than PGP are present in tumor cells
of untreated patients. The high interindividual variabil-
ity of expression/activity indicate, that the measured
parameters may contribute to resistance to variable
degrees in different tissues. The relationship between
DRPs and clinical as well as pathological characteristics
in breast cancer has been studied by several authors, so
far with contradictory results [11, 22, 23, 26, 27]. In the
present study ATase activity was increased in tumor
tissue, a finding which to our knowledge is new for
breast cancer, but matches the findings reported in non
small cell lung cancer [9]. An association of ATase
activity with any of the other characteristics considered
was not apparent in our untreated patients. We think,
however, that the role of ATase in breast cancer merits
further investigation, e.g., it would be interesting to
know whether ATase is upregulated in tumor tissue of
women treated with DNA-damaging agents. This would,
however, require follow-up tumor samples, which is
clinically rarely justified.
Most authors agree that GSH and its associated
enzymes are overexpressed in human breast cancer in
comparison with tumor-free breast tissue [28, 12]. Fur-
thermore we observed a correlation of GPx with GSH
and GST in tumor as well as in tumor-free tissue. The
significant correlations between these three related
parameters may point out the presence of common
regulatory elements [29].
In our patients GSH levels were higher in grade 1
when compared to grade 2 or 3 tumors. In the subgroup
of EBC 'high' GSH levels were associated with age > 60
years and in LABC with grade 1 and 2 tumors. GST was
significantly higher in EBC when compared to LABC or
metastatic disease. In contrast, low levels of GSH or
GST activity seemed to be associated with a more malig-
nant phenotype of tumor cells or more advanced dis-
ease. When analyzed for prognosis, 'high' GST in EBC
and 'high' GPx in LABC showed a borderline associa-
tion with longer disease-free survival. This finding was
unexpected but similar to observations made in leuke-
mias [30]. So far 'high' GST-levels in tumor tissue have
been assumed to be associated with poor prognosis,
although a significant correlation has been rarely found
[11]. One reason why our observations differ from those
of Gilbert et al. may be that our population consisted
mainly of elderly women (median age: 68 years). Fur-
thermore it may be that the expression of GSH and its
associated enzymes is hormone dependent as it has been
shown in endometrium cancer [31]. Such a hormone
dependent modulation, which is not taken into account
in any of these studies, may influence the interpretation
of the results [32].
We conclude that high levels of potential DRPs such
as PGP, GSH, GST, GPx and ATase in tumor tissue of
newly diagnosed, untreated breast cancer are part of the
phenotype of the malignant cells and are a reflection of
their constitutive characteristics. Overexpression/activ-
ity of potential DRPs does not necessarily explain if and
how they function as DRP modulators in clinical drug
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resistance. In addition EBC and LABC as well as pri-
marily metastatic disease may have their own specific
pattern of potential DRP composition. Our findings
illustrate the difficulty to associate single biological
parameters with prognosis. DRPs appear to be a com-
plex system of partly interdependent parameters, most
likely with none of them being exclusively responsible
for treatment outcome. Studies which aim at circum-
venting drug resistance by adding only one modulating
agent to standard chemotherapy may therefore ulti-
mately fail [3, 33]. If significant impacts on clinical out-
come are expected from future studies on human tumor
tissue samples so that 'bench work' can be translated
into therapy recommendations for the patient, it will
be necessary to standardize laboratory assays and to
study a representative variety of markers prospectively
in larger and more homogeneous patient groups.
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